Study to compare GW815SF [salmeterol/fluticasone-propionate] HFA MDI [hydrofluoroalkane metered-dose inhaler] with concomitant treatment with salmeterol xinafoate DPI [dry powder inhaler] plus fluticasone propionate DPI and to assess long-term safety of GW815SF HFA MDI.
Phase of Trial: Phase III
Latest Information Update: 05 Aug 2016
At a glance
- Drugs Salmeterol/fluticasone propionate (Primary) ; Fluticasone propionate; Salmeterol
- Indications Asthma
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 18 Aug 2009 Actual patient number (51) added as reported by ClinicalTrials.gov.
- 15 Oct 2008 Actual start date changed from Mar 2007 to Apr 2007 as reported by ClinicalTrials.gov.
- 14 Jul 2008 The actual end date is now 1 Jan 2008 as reported by ClinicalTrials.gov.